<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00827307</url>
  </required_header>
  <id_info>
    <org_study_id>D8666L00002</org_study_id>
    <nct_id>NCT00827307</nct_id>
  </id_info>
  <brief_title>Zoladex Plus Tamoxifen in Breast Cancer</brief_title>
  <official_title>The Effects of Adjuvant Zoladex Plus Tamoxifen on Breast Density in Pre- or Peri-menopausal Women With Early-stage Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare Zoladex plus tamoxifen with tamoxifen alone as&#xD;
      adjuvant hormonal therapy in pre- or perimenopausal women with early-stage breast cancer in&#xD;
      terms of breast density, estrogen levels, lipidemia, endometrial thickness and&#xD;
      ultrasonographic abnormalities.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After the completion of primary treatment(surgery and/or adjuvant chemotherapy, radiotherapy&#xD;
      could be given concurrently with study medication), eligible patients will be randomized to&#xD;
      receive Zoladex plus tamoxifen or tamoxifen alone. The duration of study medication along&#xD;
      with the follow-up will be 18 months, or until disease recurrence,or discontinuation of study&#xD;
      therapy (as a result of an adverse event, a patient's request, or an investigator's&#xD;
      decision), further treatment will be at investigator's discretion.&#xD;
&#xD;
      During the study period, contralateral mammograms and transvaginal ultrasound will be&#xD;
      undertaken at baseline and after 6, 12 and 18 months of study medications. Mammographic&#xD;
      density assessment will be undertaken by a single radiologist. Serum measurements including&#xD;
      estrogen levels and lipidemia will be obtained at baseline and after 3, 6, 12 and 18 months&#xD;
      of study medications.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mammographic percentage density at 18months</measure>
    <time_frame>18months after enrolled</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>estrogen levels, lipidemia, endometrial thickness and ultrasonographic abnormalities</measure>
    <time_frame>3,6,12,18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Mammography</condition>
  <condition>Estrogen</condition>
  <condition>Lipemia</condition>
  <condition>Endometrium</condition>
  <condition>Ultrasonography</condition>
  <arm_group>
    <arm_group_label>Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the combination arm, patients receive ZOLADEX 3.6 mg by subcutaneous injection every 4 weeks along with once-daily oral dose of tamoxifen 20 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conctrol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the monotherapy arm, patients receive once-daily oral dose of tamoxifen 20 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen</intervention_name>
    <description>In the monotherapy arm, patients receive once-daily oral dose of tamoxifen 20 mg.</description>
    <arm_group_label>Conctrol</arm_group_label>
    <other_name>TAM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Goserelin</intervention_name>
    <description>In the combination arm, patients receive ZOLADEX 3.6 mg by subcutaneous injection every 4 weeks along with once-daily oral dose of tamoxifen 20 mg</description>
    <arm_group_label>Combination</arm_group_label>
    <other_name>ZOLADEX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  provision of informed consent&#xD;
&#xD;
          -  histologically proven HR+ operable invasive breast cancer&#xD;
&#xD;
          -  completion of surgery and chemotherapy(if given).&#xD;
&#xD;
          -  women defined as pre- or perimenopausal according to all of the following: aged 50&#xD;
             years or younger, at least one menstrual period during the last months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  clinical evidence of metastatic disease&#xD;
&#xD;
          -  pregnancy or breast-feeding&#xD;
&#xD;
          -  bilateral oophorectomy;&#xD;
&#xD;
          -  radiation of the ovaries&#xD;
&#xD;
          -  patients who, for whatever reason(eg, confusion, infirmity,alcoholism),are unlikely to&#xD;
             comply with trial requirements&#xD;
&#xD;
          -  patients whose chemotherapy was started more than 8 weeks after completion of primary&#xD;
             surgery or whose chemotherapy was completed more than 8 weeks before starting the&#xD;
             study treatment. Chemotherapy, if given, should have been given post-operatively, ie,&#xD;
             patients who received neoadjuvant chemotherapy are ineligible&#xD;
&#xD;
          -  patients who have not received chemotherapy and whose primary surgery was completed&#xD;
             more than 8 weeks before starting the study treatment&#xD;
&#xD;
          -  previous hormonal therapy as adjuvant treatment for breast cancer&#xD;
&#xD;
          -  patients unwilling to stop taking any drug known to affect sex hormonal status, or in&#xD;
             whom it would be inappropriate to stop&#xD;
&#xD;
          -  previous history of invasive malignancy within the last 5 years, other than squamous&#xD;
             or basal cell carcinoma of the skin or carcinoma in situ of the cervix, adequately&#xD;
             cone biopsied&#xD;
&#xD;
          -  treatment with a non-approved or experimental drug during 1 month before entry into&#xD;
             the study&#xD;
&#xD;
          -  history of hypersensitivity to active or inactive excipients of tamoxifen and Zoladex&#xD;
&#xD;
          -  history of bleeding diathesis (ie. Disseminated intravascular coagulation, clotting&#xD;
             factor deficiency), or long term anticoagulant therapy (other than antiplatelet&#xD;
             therapy and low dose warfarin )&#xD;
&#xD;
          -  leukopenia and/or thrombocytopenia&#xD;
&#xD;
          -  history of ocular fundus diseases&#xD;
&#xD;
          -  history of thromboembolic diseases&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hong-Jian Yang, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Provicial Cancer Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiang-Yun Zong, MD., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Cancer Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <study_first_submitted>January 21, 2009</study_first_submitted>
  <study_first_submitted_qc>January 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2009</study_first_posted>
  <last_update_submitted>August 5, 2011</last_update_submitted>
  <last_update_submitted_qc>August 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Yang Hong-Jian, Zong Xiang-Yun</name_title>
    <organization>Zhejiang Cancer Hospital</organization>
  </responsible_party>
  <keyword>breast carcinoma; goserelin; Mammographic density</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Goserelin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

